Novartis | Себестоимость



Cost Of Sales Изменить Дата
AbbVie USD 4.4B 184M 2024-12
Alcon AG USD 1.12B 34M 2024-12
Almirall EUR 16.73M 73.47M 2024-06
Amgen USD 3.11B 198M 2024-12
AstraZeneca USD 2.72B 263M 2024-12
Autolus Therapeutics Ltd 11.39M 11.26M 2024-12
Bayer EUR 5.72B 633M 2024-12
Biogen USD 583.5M 55.2M 2024-12
Bristol-Myers Squibb USD 3.21B 356M 2024-12
Eli Lilly USD 2.4B 233M 2024-12
Fresenius EUR 4.22B 212M 2024-12
Fresenius Medical Care EUR 3.81B 200M 2024-12
Galapagos EUR 112.93M 112.91M 2024-12
Genmab DKK 337M 64M 2024-12
Gilead Sciences USD 1.58B 7M 2024-12
GlaxoSmithKline GBP 2.56B 162M 2024-12
GRIFOLS EUR 1.21B 143.12M 2024-12
Hikma Pharmaceutical USD 813M 39M 2024-06
J&J USD 7.11B 151M 2024-12
Lonza CHF 1.94B 858M 2024-06
Merck EUR 2.32B 197M 2024-12
Merck USD 3.71B 181M 2024-12
Novartis USD 3.32B 90M 2024-12
Novartis USD 3.31B 73M 2024-12
Novo Nordisk 11.31B 1.03B 2024-09
Orion EUR 167.1M 15.2M 2024-12
Pfizer USD 5.65B 781M 2024-12
Philips EUR 3.08B 710M 2024-12
Recordati EUR 172.29M 19.33M 2024-09
Regeneron Pharmaceuticals USD 565.4M 74.3M 2024-12
Roche Holding CHF 4.13B 393.5M 2024-12
Sanofi EUR 4.08B 675M 2024-09
UCB EUR 425.5M 479.5M 2024-06



Novartis Себестоимость - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Apr 2025.